Danaher (DHR) has just posted its Q2 2026 numbers, with revenue at US$6.3b and basic EPS of US$1.23, alongside trailing twelve month revenue of US$25.1b and EPS of US$5.64. Together, these figures frame the quarter within a broader earnings run rate. Over recent periods, the company has seen revenue move from US$5.9b in Q2 2025 to US$6.3b in Q2 2026, while quarterly EPS has shifted from US$0.77 to US$1.23, giving investors a clear sense of how the top and bottom lines are tracking into this latest release. With trailing net profit margins higher than a year ago and earnings growth outpacing revenue, the setup puts profitability and execution firmly in focus for this earnings season.

See our full analysis for Danaher.

With the headline figures on the table, the next step is to see how these results line up with the widely followed narratives around Danaher’s growth, profitability, and risk profile, and where those storylines may need updating.

Danaher margin profile backs profit story

• On a trailing basis, Danaher’s net profit margin sits at 15.9% versus 14.2% a year earlier, alongside trailing revenue of US$25.1b and net income of US$4.0b.
• Bulls often point to Danaher as a resilient healthcare tools platform, and the margin lift adds some weight to that, but it also sets a higher bar:
  • The combination of 15.9% margins and trailing EPS of US$5.64 lines up with the idea of a solid profitability base, rather than a one off spike tied only to Q2’s US$870 million net income.
  • At the same time, margin gains have come while trailing revenue moved from US$24.0b to US$25.1b. Bullish arguments about quality growth now need to account for whether this balance between growth and profitability can be kept up if revenue continues to grow at about 7.2% per year.

To see how these profitability trends fit into the wider story investors are building around Danaher, including more detailed margin checks and long term assessments, take a look at the Curious how numbers become stories that shape markets? Explore Community Narratives.

Revenue growth trails EPS progress

• Reported earnings grew about 16.8% over the past year while revenue growth is described at around 7.2% per year, so earnings are rising faster than the top line even though revenue of US$6.3b in Q2 2026 is only modestly above the US$5.9b level in Q2 2025.
• What stands out for a bullish view is the gap between earnings and revenue growth, which both supports and tests the story:
  • Support for the optimistic angle comes from earnings per share running at US$5.64 on a trailing basis versus quarterly EPS levels around US$1.23 to US$1.67 across recent periods, which suggests that profitability over the full year is stronger than any single three month snapshot.
  • On the other hand, with revenue growth running below the referenced 12.8% US market forecast, bulls who focus on Danaher as a growth stock need to weigh whether a roughly 16.7% earnings growth outlook can continue when the top line is moving at a slower 7.2% pace.

Valuation and debt set up a mixed picture

• Danaher trades on a P/E of 31.6x, below the Global Life Sciences average of 36.3x and a peer average of 40x, with a DCF fair value of US$226.25 and an analyst price target of US$228.61 compared with a current share price of US$179.14, while a high level of debt is flagged as a minor financial risk.
• For a more cautious, bearish leaning take, the tension is between these valuation signals and the balance sheet:
  • On one side, trading about 20.8% below the DCF fair value and below the cited analyst target implies that, if the trailing EPS of US$5.64 and 15.9% margin are sustained, the stock is not priced like the higher multiple peers in its sector.
  • On the other side, critics highlight that the high debt level, even if described as a minor risk, leaves less room for comfort if revenue growth continues to run at roughly 7.2% per year while the market is implicitly counting on earnings to grow near 16.7% annually.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Danaher's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If the mixed signals around Danaher leave you undecided, take a moment to review the full data, weigh the trade offs, and see the 4 key rewards and 1 important warning sign.

See What Else Is Out There Beyond Danaher

While Danaher posts higher earnings relative to revenue, questions remain around slower top line progress, reliance on margin strength, and a balance sheet flagged for higher debt.

If Danaher's debt flagged balance sheet and reliance on earnings outpacing revenue growth give you pause, compare that profile with companies in the solid balance sheet and fundamentals stocks screener (49 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.